A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer
Not Applicable
- Conditions
- ocally advanced pancreatic cancer
- Registration Number
- JPRN-UMIN000026525
- Lead Sponsor
- Chiba Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Severe concurrent disease (2)Interstitial pneumonia or severe pulmonary emphysema (3)Clinically significant mental disorder (4)Active concomitant malignancy (5)Moderate or severe diarrhea, hemorrhagic colitis or peptic ulcer (6)Infection requiring systemic treatment (7)Fever of 38 degrees centigrade or higher (8)Pregnant or lactating females (9)Under treatment with systemic steroid or immunosuppressive agent (10)Severe drug hypersensitivity (11)Regular use of phenytoin, warfarin or frucitocin (12)Gr2 or more peripheral sensory neuropathy (13)Inappropriate for entry onto the study, as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method